Champions Oncology (CSBR) vs OKYO Pharma (OKYO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Champions Oncology (CSBR) has outperformed OKYO Pharma (OKYO) over the past year, losing 25.4% versus a loss of 30.5%. OKYO Pharma is the larger company by market cap ($74.0 million vs $67.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CSBR | OKYO |
|---|---|---|
| Share price | $4.88 | $1.41 |
| Market cap | $67.92M | $74.00M |
| 1-day change | -2.59% | -3.42% |
| YTD return | -29.38% | -31.88% |
| 1-year return | -25.38% | -30.54% |
| 5-year return | -51.59% | — |
| Forward P/E | 48.80 | — |
| EPS (TTM) | $-0.07 | $-0.24 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.31 | $3.20 |
| 52-week low | $4.59 | $1.27 |
| Distance from 52-week high | -41.28% | -55.94% |
| Average volume | 11.25K | 104.86K |
| Shares outstanding | 13.92M | 52.48M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
CSBR vs OKYO FAQ
Which is bigger, Champions Oncology or OKYO Pharma?
OKYO Pharma (OKYO) is larger, with a market capitalization of $74.00M compared with $67.92M for Champions Oncology (CSBR).
Which stock has performed better over the past year, CSBR or OKYO?
CSBR returned -25.38% over the past 12 months, compared with -30.54% for OKYO (price return, excluding dividends). Past performance does not predict future results.
Are Champions Oncology and OKYO Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.